Combination With Treg Levels and CMR to Assess the Severity and Prognosis of Reperfusion Injury After PPCI in STEMI Patients

Combination With Regulatory T Cell Levels and Cardiac Magnetic Resonance Imaging (CMR) to Assess the Severity and Prognosis of Reperfusion Injury After Primary PCI in STEMI Patients (TregCMRRS)

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03939338

Acronym

TregCMRRS

Enrollment

250

Registered

2019-05-06

Start date

2019-07-01

Completion date

2021-08-31

Last updated

2019-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Reperfusion Injury, Myocardial, STEMI - ST Elevation Myocardial Infarction

Brief summary

This study aims to determine whether combination with regulatory T cell (Treg) levels and cardiac magnetic resonance imaging (CMR) are predictive of the severity of reperfusion injury following myocardial infarction and the prognosis in STEMI patients receiving primary percutaneous coronary intervention (PPCI).

Interventions

OTHERTreg levels and CMR results

This is an observational study. Exposure: Different Treg levels and CMR results.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Confirmed STEMI diagnosis * Undergoing primary percutaneous coronary intervention (presenting \<12 hours after symptom onset) * Patients were able to complete cardiac magnetic resonance imaging (CMR) and speckle tracking imaging echocardiogram (STE) examinations * Patients agreed and provided informed consent

Exclusion criteria

* Previous myocardial infarction or revascularization (PCI or CABG) * Congestive heart failure with LVEF\<40% * Atrial fibrillation * Renal insufficiency (GFR \< 30 ml/min/1.73m\^2) * Acute infectious diseases within nearly 3 months * Rheumatic immune system diseases * Malignant tumors * Claustrophobia * Contraindicated to CMR * Patients do not agree to be included in the study

Design outcomes

Primary

Measure	Time frame	Description
MACE (major adverse cardiovascular events)	12 months	nonfatal or fatal myocardial infarction, revascularization, cardiac death, nonfatal or fatal stroke, all cause of death

Secondary

Measure	Time frame	Description
adverse cardiac remodeling	6 months	a cut-off value of 12% change in left ventricular end-diastolic volume between the acute and follow-up magnetic resonance scans

Countries

China

Contacts

Primary ContactHongwei Li, M.D.

lhw19656@sina.com0086 10 63139780

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 8, 2026